P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study
Title:
P-286 Metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel (nab-P), bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer (MPC): an open-label, multicenter, single-arm, phase 1/2 study
Author:
Vincent, Picozzi Caio, Rocha Lima Vaibhav, Sahai Diane, Simeone Allyson, Ocean Philip, Philip Wasif, Saif Aparna, Kalyan Michael, Ondovik Jack, Shiansong Li Victoria, Manax